Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal Oxaliplatin in Neoadjuvant Treatment of Peritoneal Carcinomatosis of Colorectal Origin
NCT03253133Phase 1Completed
- Sponsor
- Institut du Cancer de Montpellier
- Start
- May 2016
- Primary completion
- Oct 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxaliplatin in colorectal cancer (CRC), appendix cancer and peritoneal carcinomatosis (PC), sponsored by Institut du Cancer de Montpellier. Primary endpoint: Maximum Tolerated Dose at 3 years. Started May 2016; status: completed.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)appendix cancerperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT03253133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03253133.